158 related articles for article (PubMed ID: 28719434)
1. Primary Cutaneous Small/Medium CD4+ T-CELL Lymphoproliferative Disorder Occurring in a Patient With Metastatic Melanoma.
Davick JJ; Gaughan E; Barry M; Gru AA
Am J Dermatopathol; 2018 Jan; 40(1):60-63. PubMed ID: 28719434
[TBL] [Abstract][Full Text] [Related]
2. Primary cutaneous small/medium CD4+ T-Cell lymphoma occurring during treatment with vemurafenib for advanced melanoma.
Garrido MC; Riveiro-Falkenbach E; Ruano Y; Ortiz P; Rodriguez-Peralto JL
Am J Dermatopathol; 2015 Jun; 37(6):440-3. PubMed ID: 25357018
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
Sinha R; Larkin J; Gore M; Fearfield L
Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
[TBL] [Abstract][Full Text] [Related]
4. Development of a biclonal cutaneous T-cell lymphoproliferative process during treatment with immune checkpoint inhibitors for metastatic melanoma.
Davick JJ; Wick MR; Gru AA
Melanoma Res; 2017 Aug; 27(4):383-386. PubMed ID: 28574977
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
6. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy-induced leukoderma from treatment of melanoma with IL-2: a case report and a review of the literature.
Gathings R; Lewallen R; Yosipovitch G
Acta Derm Venereol; 2015 Feb; 95(2):197-200. PubMed ID: 24820241
[TBL] [Abstract][Full Text] [Related]
8. Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2.
Ma C; Armstrong AW
J Dermatolog Treat; 2014 Oct; 25(5):401-8. PubMed ID: 23763243
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib-induced pityriasis amiantacea: a case report.
Bilgiç Ö
Cutan Ocul Toxicol; 2016 Dec; 35(4):329-31. PubMed ID: 26513697
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
11. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
Keating GM; Lyseng-Williamson KA
Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
[TBL] [Abstract][Full Text] [Related]
12. [Vemurafenib (Zelboraf) in the therapy of melanoma].
Liszkay G
Magy Onkol; 2013 Jun; 57(2):110-3. PubMed ID: 23795356
[TBL] [Abstract][Full Text] [Related]
13. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
[TBL] [Abstract][Full Text] [Related]
14. A case of vemurafenib-induced polyarhritis in a patient with melanoma: how to manage it?
Babacan T; Türkbeyler IH; Balakan O; Pehlivan Y; Suner A; Kısacık B
Int J Rheum Dis; 2017 Mar; 20(3):398-401. PubMed ID: 24815010
[TBL] [Abstract][Full Text] [Related]
15. Painful nipple hyperkeratosis secondary to vemurafenib.
Carr ES; Brown SC; Fiala KH
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28211633
[TBL] [Abstract][Full Text] [Related]
16. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
17. A model for cutaneous squamous cell carcinoma in vemurafenib therapy.
Kent R; Glorioso S; Nordberg ML
J La State Med Soc; 2012; 164(6):311-3. PubMed ID: 23431672
[TBL] [Abstract][Full Text] [Related]
18. Vemurafenib. Value unclear in metastatic melanoma.
Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
[TBL] [Abstract][Full Text] [Related]
19. Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma.
Mangold AR; Bryce A; Sekulic A
J Am Acad Dermatol; 2014 Nov; 71(5):e205-6. PubMed ID: 25437992
[No Abstract] [Full Text] [Related]
20. [Metastatic melanoma: some hope from ipilimumab and vemurafenib].
Piérard-Franchimont C; Piérard GE
Rev Med Liege; 2012 Feb; 67(2):64-8. PubMed ID: 22482234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
